专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL283945D0 Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof 未知
公开(公告)号：IL283945D0
公开(公告)日：2021-07-29
申请号：IL28394521
申请日：2021-06-13
申请人： REGENERON PHARMA , MURPHY ANDREW J , SKOKOS DIMITRIS , WAITE JANELLE , ULLMAN ERICA , HERMANN AYNUR , SMITH ERIC , OLSON KARA , WEI JOYCE , YANCOPOULOS GEORGE D
发明人： MURPHY ANDREW J , SKOKOS DIMITRIS , WAITE JANELLE , ULLMAN ERICA , HERMANN AYNUR , SMITH ERIC , OLSON KARA , WEI JOYCE , YANCOPOULOS GEORGE D
IPC分类号： A61K39/00 , A61K39/395 , A61P35/00 , A61P35/02 , C07K16/28 , C07K16/30 , C12N15/63
摘要： The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.

2. 发明专利

IL286536D0 Egfr x cd28 multispecific antibodies 未知
公开(公告)号：IL286536D0
公开(公告)日：2021-10-31
申请号：IL28653621
申请日：2021-09-19
申请人： REGENERON PHARMA , SKOKOS DIMITRIS , MURPHY ANDREW J , YANCOPOULOS GEORGE D , HABER LAURIC , LIN CHIA YANG
发明人： SKOKOS DIMITRIS , MURPHY ANDREW J , YANCOPOULOS GEORGE D , HABER LAURIC , LIN CHIA-YANG
IPC分类号： A61K9/00 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/28 , C07K16/30 , C07K16/40 , C12N5/071
摘要： The present invention provides multispecific antibodies that bind to EGFR and CD28 (EGFRxCD28) as well as anti-EGFR antibodies. Such antibodies may be combined with a further therapeutic agent such as an anti-PD1 antibody. Methods for treating cancers (e.g., EGFR-expressing cancer) by administering the antibodies (e.g., and combinations thereof with anti-PD1) are also provided. The EGFRxCD28 antibodies of the present invention embody a tumor-targeted immunotherapeutic modality combined with PD-1 inhibition. These bispecific antibodies bind a tumor-specific antigen (TSA) (EGFR) with one arm and the co-stimulatory receptor, CD28, on T-cells with the other arm. Combination therapy with PD-1 inhibitors specifically potentiated intra-tumoral T cell activation, promoting an effector memory-like T cell phenotype without systemic cytokine secretion in a variety of syngeneic and human tumor xenograft models. Combining this class of CD28-co-stimulatory bispecific antibodies with the clinically validated anti-PD-1 treatment provides a well-tolerated antibody therapy with markedly enhanced anti-tumor efficacy.

3. 发明申请

WO2011094467A2 METHODS OF TREATING DIABETES WITH DLL4 ANTAGONISTS 审中-公开
标题翻译：用DLL4拮抗剂治疗糖尿病的方法
公开(公告)号：WO2011094467A2
公开(公告)日：2011-08-04
申请号：PCT/US2011/022817
申请日：2011-01-28
申请人： REGENERON PHARMACEUTICALS, INC. , SKOKOS, Dimitris
发明人： SKOKOS, Dimitris
IPC分类号： C07K16/22
CPC分类号： C07K16/28 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/73
摘要： The present invention provides methods of preventing, treating or ameliorating diabetes by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways. As observed in a mouse model of diabetes, Dll4 antagonists exhibit protective effects on pancreatic islets, lower blood glucose levels, and block the production of auto-antibodies, including those against insulin and glutamic acid decarboxylase 65 (GAD65), via the expansion of regulatory T cells (Tregs). Thus, the present invention further provides methods of lowering the levels of blood glucose, and/or reducing or blocking the production of auto-antibodies, by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like.
摘要翻译：本发明提供了通过向有需要的受试者施用阻断Dll4-Notch信号通路的治疗有效量的Dll4拮抗剂来提供预防，治疗或改善糖尿病的方法。如在糖尿病的小鼠模型中观察到的，Dll4拮抗剂通过扩大调节物质对胰岛发挥保护作用，降低血糖水平，并阻断自身抗体的产生，包括针对胰岛素和谷氨酸脱羧酶65（GAD65）的抗体 T细胞（Tregs）。因此，本发明还通过向有需要的受试者施用治疗有效量的Dll4拮抗剂，进一步提供降低血糖水平和/或降低或阻断自身抗体产生的方法。用于本发明的合适的Dll4拮抗剂包括特异性结合Dll4并阻断Dll4-Notch相互作用的抗体或抗体片段，Dll4的细胞外结构域等。

4. 发明申请

WO2011094465A4 METHODS OF TREATING AUTOIMMUNE DISEASES WITH DLL4 ANTAGONISTS 审中-公开
标题翻译：用DLL4拮抗剂治疗自身免疫性疾病的方法
公开(公告)号：WO2011094465A4
公开(公告)日：2011-08-04
申请号：PCT/US2011/022810
申请日：2011-01-28
申请人： REGENERON PHARMACEUTICALS, INC. , SKOKOS, Dimitris
发明人： SKOKOS, Dimitris
IPC分类号： C07K16/22 , A61K39/395 , A61P37/00
摘要： The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory T cell (Treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of Dll4 antagonists that block DII4-Notch signal pathways, thereby increasing the number of Treg. Diseases or disorders treatable by the methods of the invention include autoimmune diseases or disorders, such as multiple sclerosis (MS), diabetes, and the like. Suitable DII4 antagonists for the invention include antibodies or antibody fragments that specifically bind DII4 and block DII4- Notch interactions, the extracellular domain of DII4, and the like. The invention also provides methods of preventing an occurrence or recurrence of such diseases or disorders in a subject predisposed or susceptible to developing such diseases or disorders. Furthermore, the methods of the invention are useful in preventing or treating organ transplant rejections or graft- versus-host disease.
摘要翻译：本发明提供了治疗疾病或病症的方法，其中通过向患有这种疾病或病症的受试者施用治疗有效的疾病或病症，其中增加调节性T细胞（Treg）的数量是有益的阻断Dll4-Notch信号途径的Dll4拮抗剂的量，由此增加Treg的数量。通过本发明的方法可治疗的疾病或病症包括自身免疫性疾病或病症，例如多发性硬化症（MS），糖尿病等。用于本发明的合适的Dll4拮抗剂包括特异性结合Dll4和阻断Dll4-Notch相互作用的抗体或抗体片段，Dll4的胞外结构域等。本发明还提供了预防易患或易患发生此类疾病或病症的受试者中此类疾病或病症的发生或复发的方法。此外，本发明的方法可用于预防或治疗器官移植排斥反应或移植物抗宿主疾病。

5. 发明申请

WO2011094467A3 METHODS OF TREATING DIABETES WITH DLL4 ANTAGONISTS 审中-公开
标题翻译：用DLL4拮抗剂治疗糖尿病的方法
公开(公告)号：WO2011094467A3
公开(公告)日：2011-12-22
申请号：PCT/US2011022817
申请日：2011-01-28
申请人： REGENERON PHARMA , SKOKOS DIMITRIS
发明人： SKOKOS DIMITRIS
IPC分类号： C07K16/22 , A61K39/395 , A61P3/10 , A61P37/00
CPC分类号： C07K16/28 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/73
摘要： The present invention provides methods of preventing, treating or ameliorating diabetes by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways. As observed in a mouse model of diabetes, Dll4 antagonists exhibit protective effects on pancreatic islets, lower blood glucose levels, and block the production of auto-antibodies, including those against insulin and glutamic acid decarboxylase 65 (GAD65), via the expansion of regulatory T cells (Tregs). Thus, the present invention further provides methods of lowering the levels of blood glucose, and/or reducing or blocking the production of auto-antibodies, by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like.
摘要翻译：本发明提供了通过向有需要的受试者施用治疗有效量的阻断Dll4-Notch信号通路的Dll4拮抗剂来预防，治疗或改善糖尿病的方法。如在糖尿病小鼠模型中观察到的，Dll4拮抗剂通过监管的扩展对胰岛具有保护作用，降低血糖水平并阻断自身抗体（包括针对胰岛素和谷氨酸脱羧酶65（GAD65）的自身抗体）的产生 T细胞（Tregs）。因此，本发明进一步提供了通过向有需要的受试者施用治疗有效量的Dll4拮抗剂来降低血糖水平和/或减少或阻断自身抗体产生的方法。适用于本发明的Dll4拮抗剂包括特异性结合Dll4并阻断Dll4-Notch相互作用的抗体或抗体片段，Dll4的胞外结构域等。

6. 发明申请

WO2012064682A1 HUMAN ANTIBODIES TO HUMAN TNF-LIKE LIGAND 1A (TL1A) 审中-公开
标题翻译：人类TNF-likeLigand 1A（TL1A）人类抗体
公开(公告)号：WO2012064682A1
公开(公告)日：2012-05-18
申请号：PCT/US2011/059675
申请日：2011-11-08
申请人： REGENERON PHARMACEUTICALS, INC. , CLASSON, Brendan, J. , SKOKOS, Dimitris
发明人： CLASSON, Brendan, J. , SKOKOS, Dimitris
IPC分类号： C07K16/28
CPC分类号： C07K16/2875 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1 A antibodies are useful in treating diseases or disorders associated with TL1 A, such as inflammatory diseases or disorders, such as inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.
摘要翻译：提供了特异性结合并抑制人TNF-样配体1A（hTL1A）的人抗体的完全人抗体或抗原结合片段。人抗hTL1A抗体可用于治疗与TL1A相关的疾病或病症，例如炎性疾病或病症，例如炎性肠病，包括溃疡性结肠炎和克罗恩病，类风湿性关节炎等; 自身免疫疾病或病症，如多发性硬化，糖尿病等; 和过敏反应，如哮喘和过敏性肺部炎症。

7. 发明申请

WO2011094465A1 METHODS OF TREATING AUTOIMMUNE DISEASES WITH DLL4 ANTAGONISTS 审中-公开
标题翻译：用DLL4拮抗剂治疗自身免疫疾病的方法
公开(公告)号：WO2011094465A1
公开(公告)日：2011-08-04
申请号：PCT/US2011022810
申请日：2011-01-28
申请人： REGENERON PHARMA , SKOKOS DIMITRIS
发明人： SKOKOS DIMITRIS
IPC分类号： C07K16/22 , A61K39/395 , A61P37/00
CPC分类号： C07K16/28 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/73
摘要： The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory T cell (Treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of DII4 antagonists that block DII4-Notch signal pathways, thereby increasing the number of Treg. Diseases or disorders treatable by the methods of the invention include autoimmune diseases or disorders, such as multiple sclerosis (MS), diabetes, and the like. Suitable DII4 antagonists for the invention include antibodies or antibody fragments that specifically bind DII4 and block DII4- Notch interactions, the extracellular domain of DII4, and the like. The invention also provides methods of preventing an occurrence or recurrence of such diseases or disorders in a subject predisposed or susceptible to developing such diseases or disorders. Furthermore, the methods of the invention are useful in preventing or treating organ transplant rejections or graft- versus-host disease.
摘要翻译：本发明提供了治疗疾病或病症的方法，其中通过向患有这种疾病或病症的受试者施用治疗有效量的DII4拮抗剂来阻断DII4-拮抗剂，其中增加调节性T细胞（Treg）的数量是有益的， Notch信号通路，从而增加Treg的数量。可通过本发明的方法治疗的疾病或病症包括自身免疫性疾病或病症，例如多发性硬化症（MS），糖尿病等。用于本发明的合适的DII4拮抗剂包括特异性结合DII4并阻断DII4-Notch相互作用的抗体或抗体片段，DII4的细胞外结构域等。本发明还提供了预防易感发展或易于发展此类疾病或病症的受试者中这种疾病或病症发生或复发的方法。此外，本发明的方法可用于预防或治疗器官移植排斥或移植物抗宿主病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式